Related Experiment Video
Updated: Dec 10, 2025
16:40
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
26.7K
Discussing deactivation of implantable cardiac defibrillators
1Department of Cardiology, Hillingdon Hospital, Uxbridge, UK.
British Journal of Hospital Medicine (London, England : 2005)
|August 27, 2020
Summary
Deactivating implantable cardioverter defibrillators (ICDs) is crucial for patients with life-limiting conditions. This article explores the background and practical considerations for ICD deactivation decisions.
Area of Science:
- Cardiology
- Medical Ethics
- Geriatrics
Background:
- Implantable cardiac defibrillators (ICDs) are vital for preventing sudden cardiac death in patients with life-threatening arrhythmias.
- Patients with ICDs often develop life-limiting conditions due to aging, frailty, and progressive cardiac or non-cardiac morbidity.
- This progression presents a significant challenge regarding decisions to deactivate ICDs.
Purpose of the Study:
- To discuss the background and rationale for deactivating implantable cardioverter defibrillators.
- To outline practical considerations and decision-making frameworks for ICD deactivation in patients with life-limiting illnesses.
Main Methods:
- Literature review on ICD deactivation.
- Discussion of clinical scenarios and ethical considerations.
- Analysis of practical approaches to device deactivation.
Main Results:
- Deactivation decisions require careful consideration of the patient's prognosis and quality of life.
- Ethical frameworks support deactivation when the burdens of the ICD outweigh its benefits.
- Practical guidelines are needed to assist clinicians in these complex decisions.
Conclusions:
- Deactivating implantable cardioverter defibrillators is an important aspect of end-of-life care for patients with life-limiting conditions.
- A structured approach, considering both clinical and ethical factors, is essential for appropriate ICD deactivation.
- Further guidance and discussion are needed to support healthcare professionals and patients in making these difficult decisions.
Related Concept Videos
01:23Cardiopulmonary Resuscitation III: AED Use
338
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
338
01:29Cardiomyopathy V: Interprofessional Care
182
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
182
01:25Dysrhythmias VI: Management of Dysrhythmias
268
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
268
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.5K
01:30Cardiac Action Potential
4.9K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
4.9K